US-CONGRESS BILLS-119hr2821eh: FDA Modernization Act 3.0
The FDA Modernization Act 3.0 (H.R. 2821) introduces significant changes to drug approval pathways, cGMP requirements, and DEA quota processes, aiming to reduce drug shortages and streamline generic approvals. It also updates DSCSA track-and-trace rules and establishment registration for all pharmaceutical manufacturers.
Aforeworn detected this change in the Pharmaceutical Manufacturing (FDA/DEA) space on July 22, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated High urgency. All pharmaceutical manufacturers, including branded, generic, API, contract, and 503B compounders should confirm how it applies to their specific situation before acting. There is a time constraint attached: Effective upon enactment (likely within 90 days); some provisions may have phased implementation (check FDA guidance).. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Pharmaceutical Manufacturing (FDA/DEA) continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.
What changed
New FDA Modernization Act 3.0 alters drug approval (NDA/ANDA) pathways, cGMP compliance standards, DEA quota allocation for controlled substances, DSCSA serialization requirements, and establishment registration procedures.
Who it affects
All pharmaceutical manufacturers, including branded, generic, API, contract, and 503B compounders
What you must do
Review and update quality systems, registration, and reporting processes to comply with new cGMP and DSCSA provisions; adjust DEA quota applications and controlled substance handling procedures.
Deadline
Effective upon enactment (likely within 90 days); some provisions may have phased implementation (check FDA guidance).
Source: https://www.govinfo.gov/app/details/BILLS-119hr2821eh
Never miss a change like this again
Aforeworn watches Pharmaceutical Manufacturing (FDA/DEA) around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trialRelated changes in Pharmaceutical Manufacturing (FDA/DEA)
- UPDATE: Trump Signs Executive Order to Reschedule Cannabis and Expand Federal Policy - Foley Hoag
- US-CONGRESS BILLS-119hr9599ih: Strengthening the Exercise of Controls and Upgrading Requirements for Efficiency in 340B Act; SECURE 340B Act
- US-CONGRESS S1041: Affordable Prescriptions for Patients Act
- Determination That RASUVO (Methotrexate) Solution, 27.5 Milligrams/0.55 Milliliter (27.5 Milligrams/0.55 Milliliter), Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness
- US-CONGRESS BILLS-119hr9774ih: To amend the Federal Food, Drug, and Cosmetic Act to provide for expedited approval of priority nonprescription drugs, and for other purposes.